HF
ENGN icon

HRT Financial’s enGene Therapeutics ENGN Stock Holding History

HRT Financial’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29K Sell
16,831
-15,186
-47% -$61.9K ﹤0.01% 3875
2026
Q1 		$218K Sell
32,017
-32,363
-50% -$288K ﹤0.01% 3139
2025
Q4 		$581K Buy
+64,380
New +$516K ﹤0.01% 2029

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

HRT Financial's ENGN Position: Q2 2026 in Review

HRT Financial reduced its enGene Therapeutics (ENGN) stake by 47% in Q2 2026, selling an estimated $61.9K and leaving 16,831 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #3875.

HRT Financial first reported a position in ENGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $581K in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • HRT Financial held 16,831 shares of enGene Therapeutics worth $29K as of Q2 2026.
  • HRT Financial sold 15,186 enGene Therapeutics shares in Q2 2026, an estimated $61.9K.
  • enGene Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3875 holding.
  • HRT Financial first reported a position in enGene Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • HRT Financial's enGene Therapeutics position peaked at $581K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.